Department of Surgery, Kurume University School of Medicine, Kurume, Japan;
Department of Surgery, Kurume University School of Medicine, Kurume, Japan.
Anticancer Res. 2024 Aug;44(8):3567-3575. doi: 10.21873/anticanres.17179.
BACKGROUND/AIM: There are no established biomarkers for immune checkpoint inhibitors (ICI) in colorectal cancer (CRC) with microsatellite stability (MSS) or proficient mismatch repair (pMMR). Therefore, this study aimed to identify biomarkers for ICI benefit in patients with pMMR by analyzing the down-regulated DNA repair-related genes involved in highly immunogenic and immune responses, and comparing their expression levels and clinical features.
Mismatch repair (MMR), tumor-infiltrating lymphocytes (TIL), and tumor mutation burden (TMB) were evaluated in 13 CRC cases and mRNA expression levels of 95 DNA repair-related genes were measured. DNA repair-related genes with reduced mRNA expression in the high immunogenicity and high immune response groups were identified. Then, the mRNA expression levels of the identified DNA repair-related genes were measured in 135 patients with CRC. Hierarchical cluster analysis was performed using the mRNA expression levels to compare the clinicopathological characteristics of each cluster.
ATR, LIG4, and RAD52 mRNA levels were significantly down-regulated in the high immunogenicity group. GADD45B, SMUG1, and XRCC6 mRNA levels were significantly down-regulated in the high immune response group. Cases in the cluster with reduced mRNA expression of the six genes were pMMR cases. CD8 mRNA expression level was higher in this cluster than in the other clusters.
Decreased mRNA expression levels of ATR, LIG4, RAD52, GADD45B, SMUG1, and XRCC6 genes were associated with high cytotoxic T cell and TMB levels, suggesting that these genes could serve as biomarkers for ICI efficacy in pMMR cases.
背景/目的:微卫星稳定(MSS)或错配修复功能完整(pMMR)的结直肠癌(CRC)中尚无确定的免疫检查点抑制剂(ICI)的生物标志物。因此,本研究旨在通过分析与高度免疫原性和免疫反应相关的下调 DNA 修复相关基因,确定 pMMR 患者接受 ICI 获益的生物标志物,并比较其表达水平和临床特征。
评估了 13 例 CRC 病例的错配修复(MMR)、肿瘤浸润淋巴细胞(TIL)和肿瘤突变负担(TMB),并测量了 95 个 DNA 修复相关基因的 mRNA 表达水平。鉴定高免疫原性和高免疫反应组中 mRNA 表达降低的 DNA 修复相关基因。然后,在 135 例 CRC 患者中测量了鉴定的 DNA 修复相关基因的 mRNA 表达水平。使用 mRNA 表达水平进行层次聚类分析,比较每个聚类的临床病理特征。
ATR、LIG4 和 RAD52 mRNA 水平在高免疫原性组中显著下调。GADD45B、SMUG1 和 XRCC6 mRNA 水平在高免疫反应组中显著下调。六个基因 mRNA 表达降低的病例为 pMMR 病例。该聚类中 CD8 mRNA 表达水平高于其他聚类。
ATR、LIG4、RAD52、GADD45B、SMUG1 和 XRCC6 基因的 mRNA 表达水平降低与高细胞毒性 T 细胞和 TMB 水平相关,提示这些基因可能作为 pMMR 病例中 ICI 疗效的生物标志物。